09 November2026: European Commission expands Pepaxti approval to 3L treatment
Oncopeptides has received European Commission approval for a label expansion of Pepaxti in combination with dexamethasone, allowing treatment of adults with multiple myeloma who have received at least two prior lines of therapy and whose disease is refractory to lenalidomide and their last line of treatment. The decision moves Pepaxti from fourth-line to third-line and later use, removing the previous triple-class-refractory requirement
The expanded indication is supported by phase 3 OCEAN trial data, which demonstrated significantly longer median progression-free survival with melflufen plus dexamethasone versus pomalidomide plus dexamethasone (6.8 vs. 4.9 months; HR 0.79) in relapsed/refractory multiple myeloma. The approval also incorporates safety evidence from other clinical trials and real-world use
The label expansion addresses an important treatment gap in relapsed/refractory multiple myeloma, enabling eligible patients to receive Pepaxti earlier without having to meet the previous triple-class-refractory criteria. Patients with prior autologous stem cell transplantation must have a time to progression of at least three years from transplantation
Pepaxti is a first-in-class peptide-drug conjugate, comprising melphalan flufenamide, which is designed to exploit aminopeptidase activity within tumor cells to release the alkylating agent melphalan intracellularly. This targeted delivery approach distinguishes it from conventional systemic alkylating chemotherapy
Strategically, the earlier-line expansion could substantially strengthen Pepaxti’s European commercial opportunity, with Oncopeptides estimating that removal of the triple-class-refractory requirement could double the eligible patient population. The company plans to leverage its existing commercial infrastructure, with Germany prioritized for market access and further pricing and reimbursement activities planned in markets including Spain and Italy